Summary
Amgen Inc. filed an amendment to its Form 10-Q for the quarterly period ended September 30, 2011. This amendment primarily addresses the re-filing of Exhibit 10.47, an amendment to a Master Services Agreement with International Business Machines Corporation, after discussions with the SEC regarding confidential treatment. The company has provided a revised version of the exhibit with less redaction and included its schedules and exhibits. For investors, this filing does not introduce new financial results or operational updates for the period. Its significance lies in the procedural correction and the updated disclosure of material contractual information related to Amgen's IT services. Investors should refer to the original 10-Q filing from November 4, 2011, for the company's financial performance and operational highlights for the September 30, 2011 quarter.
Financial Highlights
53 data points| Revenue | $3.94B |
| Gross Profit | $3.27B |
| SG&A Expenses | $1.13B |
| Operating Expenses | $3.42B |
| Operating Income | $525.00M |
| Interest Expense | $158.00M |
| Net Income | $454.00M |
| EPS (Basic) | $0.50 |
| EPS (Diluted) | $0.50 |
| Shares Outstanding (Basic) | 907.00M |
| Shares Outstanding (Diluted) | 914.00M |
Key Highlights
- 1This filing is an amendment (10-Q/A) to Amgen's Quarterly Report for the period ending September 30, 2011.
- 2The primary purpose of the amendment is to revise Exhibit 10.47, concerning an amendment to a Master Services Agreement with IBM.
- 3The amendment reflects updated information regarding confidential treatment of certain portions of the IBM Master Services Agreement, following SEC correspondence.
- 4The re-filed Exhibit 10.47 includes less redaction and incorporates its schedules and exhibits.
- 5No other sections of the original Form 10-Q are being amended by this filing.
- 6New certifications from the CEO and CFO pursuant to Rule 13a-14(a) are included.
- 7This amendment does not alter the financial reporting or operational insights from the original 10-Q filing.